|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Porter P: ‘Westernizing’ women's risks?
Breast cancer in lower-income countries. N Engl J Med. 358:213–216.
2008.
|
|
3
|
Tuttle TM, Rueth NM, Abbott A and Virnig
BA: United States trends in the surgical treatment of primary
breast cancer. World J Surg. 36:1475–1479. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arslan C, Altundag K and Dizdar O:
Emerging drugs in metastatic breast cancer: an update. Expert Opin
Emerg Drugs. 16:647–667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stopeck AT, Brown-Glaberman U, Wong HY,
Park BH, Barnato SE, Gradishar WJ, Hudis CA and Rugo HS: The role
of targeted therapy and biomarkers in breast cancer treatment. Clin
Exp Metastasis. 29:807–819. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jordan VC and O'Malley BW: Selective
estrogen-receptor modulators and antihormonal resistance in breast
cancer. J Clin Oncol. 25:5815–5824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Allegra JC, Lippman ME, Thompson EB and
Simon R: An association between steroid hormone receptors and
response to cytotoxic chemotherapy in patients with metastatic
breast cancer. Cancer Res. 38:4299–4304. 1978.
|
|
8
|
Kuerer HM, Newman LA, Smith TL, Ames FC,
Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N,
Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN and
Singletary SE: Clinical course of breast cancer patients with
complete pathologic primary tumor and axillary lymph node response
to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol.
17:460–469. 1999.
|
|
9
|
Conforti R, Boulet T, Tomasic G, Taranchon
E, Arriagada R, Spielmann M, Ducourtieux M, Soria JC, Tursz T,
Delaloge S, Michiels S and Andre F: Breast cancer molecular
subclassification and estrogen receptor expression to predict
efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker
study from two randomized trials. Ann Oncol. 18:1477–1483. 2007.
View Article : Google Scholar
|
|
10
|
Pritchard JE, Dillon PM, Conaway MR, Silva
CM and Parsons SJ: A mechanistic study of the effect of
doxorubicin/adriamycin on the estrogen response in a breast cancer
model. Oncology. 83:305–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dickson RB and Stancel GM: Estrogen
receptor-mediated processes in normal and cancer cells. J Natl
Cancer Inst Monogr. 2000:135–145. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lewis-Wambi JS and Jordan VC: Estrogen
regulation of apoptosis: how can one hormone stimulate and inhibit?
Breast Cancer Res. 11:2062009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Haddow A, Watkinson JM, Paterson E and
Koller PC: Influence of synthetic oestrogens on advanced malignant
disease. Br Med J. 2:393–398. 1944. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ward HW: Anti-oestrogen therapy for breast
cancer: a trial of tamoxifen at two dose levels. Br Med J. 1:13–14.
1973. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lewis JS, Meeke K, Osipo C, Ross EA,
Kidawi N, Li T, Bell E, Chandel NS and Jordan VC: Intrinsic
mechanism of estradiol-induced apoptosis in breast cancer cells
resistant to estrogen deprivation. J Natl Cancer Inst.
97:1746–1759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gompel A, Somaï S, Chaouat M, Kazem A,
Kloosterboer HJ, Beusman I, Forgez P, Mimoun M and Rostène W:
Hormonal regulation of apoptosis in breast cells and tissues.
Steroids. 65:593–598. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Teixeira C, Reed JC and Pratt MA: Estrogen
promotes chemotherapeutic drug resistance by a mechanism involving
Bcl-2 proto-oncogene expression in human breast cancer cells.
Cancer Res. 55:3902–3907. 1995.PubMed/NCBI
|
|
18
|
Perillo B, Sasso A, Abbondanza C and
Palumbo G: 17β-estradiol inhibits apoptosis in MCF-7 cells,
inducing bcl-2 expression via two estrogen-responsive
elements present in the coding sequence. Mol Cell Biol.
20:2890–2901. 2000.
|
|
19
|
Rio MC and Chambon P: The pS2 gene, mRNA,
and protein: a potential marker for human breast cancer. Cancer
Cells. 2:269–274. 1990.PubMed/NCBI
|
|
20
|
Bossenmeyer-Pourié C, Kannan R, Ribieras
S, Wendling C, Stoll I, Thim L, Tomasetto C and Rio MC: The trefoil
factor 1 participates in gastrointestinal cell differentiation by
delaying G1-S phase transition and reducing apoptosis. J Cell Biol.
157:761–770. 2002.PubMed/NCBI
|
|
21
|
Buron N, Guery L, Creuzot-Garcher C,
Lafontaine PO, Bron A, Rio MC and Solary E: Trefoil factor
TFF1-induced protection of conjunctival cells from apoptosis at
premitochondrial and postmitochondrial levels. Invest Ophthalmol
Vis Sci. 49:3790–3798. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nunez AM, Jakowlev S, Briand JP, Gaire M,
Krust A, Rio MC and Chambon P: Characterization of the
estrogen-induced pS2 protein secreted by the human breast cancer
cell line MCF-7. Endocrinology. 121:1759–1765. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tomasetto C and Rio MC: Pleiotropic
effects of Trefoil Factor 1 deficiency. Cell Mol Life Sci.
62:2916–2920. 2005.PubMed/NCBI
|
|
24
|
Ruchaud-Sparagano MH, Westley BR and May
FE: The trefoil protein TFF1 is bound to MUC5AC in human gastric
mucosa. Cell Mol Life Sci. 61:1946–1954. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Madsen J, Nielsen O, Tornøe I, Thim L and
Holmskov U: Tissue localization of human trefoil factors 1, 2, and
3. J Histochem Cytochem. 55:505–513. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thuwajit P, Chawengrattanachot W, Thuwajit
C, Sripa B, May FE, Westley BR, Tepsiri NN, Paupairoj A and Chau-In
S: Increased TFF1 trefoil protein expression in Opisthorchis
viverrini-associated cholangiocarcinoma is important for
invasive promotion. Hepatol Res. 37:295–304. 2007.PubMed/NCBI
|
|
27
|
Prest SJ, May FE and Westley BR: The
estrogen-regulated protein, TFF1, stimulates migration of human
breast cancer cells. FASEB J. 16:592–594. 2002.PubMed/NCBI
|
|
28
|
Soutto M, Belkhiri A, Piazuelo MB,
Schneider BG, Peng D, Jiang A, Washington MK, Kokoye Y, Crowe SE,
Zaika A, Correa P, Peek RM Jr and El-Rifai W: Loss of TFF1 is
associated with activation of NF-κB-mediated inflammation and
gastric neoplasia in mice and humans. J Clin Invest. 121:1753–1767.
2011.
|
|
29
|
Gillesby BE and Zacharewski TR: pS2 (TFF1)
levels in human breast cancer tumor samples: correlation with
clinical and histological prognostic markers. Breast Cancer Res
Treat. 56:253–265. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Poulsom R, Hanby AM, Lalani EN, Hauser F,
Hoffmann W and Stamp GW: Intestinal trefoil factor (TFF 3) and pS2
(TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are
co-expressed in normal, hyperplastic, and neoplastic human breast
epithelium. J Pathol. 183:30–38. 1997. View Article : Google Scholar
|
|
31
|
Reshkin SJ, Tedone T, Correale M, Mangia
A, Casavola V and Paradiso A: Association of pS2 (TFF1) release
with breast tumour proliferative rate: in vitro and in vivo
studies. Cell Prolif. 32:107–118. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Amiry N, Kong X, Muniraj N, Kannan N,
Grandison PM, Lin J, Yang Y, Vouyovitch CM, Borges S, Perry JK,
Mertani HC, Zhu T, Liu D and Lobie PE: Trefoil factor-1 (TFF1)
enhances oncogenicity of mammary carcinoma cells. Endocrinology.
150:4473–4483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Buache E, Etique N, Alpy F, Stoll I,
Muckensturm M, Reina-San-Martin B, Chenard MP, Tomasetto C and Rio
MC: Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity
of human breast cancer cells and mammary tumor development in
TFF1-knockout mice. Oncogene. 30:3261–3273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miller WR: Clinical, pathological,
proliferative and molecular responses associated with neoadjuvant
aromatase inhibitor treatment in breast cancer. J Steroid Biochem
Mol Biol. 118:273–276. 2010. View Article : Google Scholar
|
|
35
|
Zhou L, Yan T, Jiang Y, Di G, Shen Z, Shao
Z and Lu J: Prognostic and predictive value of TFF1 for adjuvant
endocrine therapy in Chinese women with early ER positive breast
cancer: comparing aromatase inhibitors with tamoxifen. Breast.
20:15–20. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sinha AK: Colorimetric assay of catalase.
Anal Biochem. 47:389–394. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kudoh K, Ramanna M, Ravatn R, Elkahloun
AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS and Chin KV:
Monitoring the expression profiles of doxorubicin-induced and
doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res.
60:4161–4166. 2000.PubMed/NCBI
|
|
38
|
Troester MA, Hoadley KA, Sorlie T, Herbert
BS, Borresen-Dale AL, Lonning PE, Shay JW, Kaufmann WK and Perou
CM: Cell-type-specific responses to chemotherapeutics in breast
cancer. Cancer Res. 64:4218–4226. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Elmore LW, Di X, Dumur C, Holt SE and
Gewirtz DA: Evasion of a single-step, chemotherapy-induced
senescence in breast cancer cells: implications for treatment
response. Clin Cancer Res. 11:2637–2643. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mobley JA and Brueggemeier RW: Estrogen
receptor-mediated regulation of oxidative stress and DNA damage in
breast cancer. Carcinogenesis. 25:3–9. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sastre-Serra J, Valle A, Company MM, Garau
I, Oliver J and Roca P: Estrogen down-regulates uncoupling proteins
and increases oxidative stress in breast cancer. Free Radic Biol
Med. 48:506–512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
O'Sullivan J, Whyte L, Drake J and
Tenniswood M: Alterations in the post-translational modification
and intracellular trafficking of clusterin in MCF-7 cells during
apoptosis. Cell Death Differ. 10:914–927. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Won YS, Lee SJ, Yeo SG and Park DC:
Effects of female sex hormones on clusterin expression and
paclitaxel resistance in endometrial cancer cell lines. Int J Med
Sci. 9:86–92. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ikeda H, Taira N, Nogami T, Shien K, Okada
M, Shien T, Doihara H and Miyoshi S: Combination treatment with
fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel,
docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic
effect in estrogen receptor-positive breast cancer. Cancer Sci.
102:2038–2042. 2011. View Article : Google Scholar
|
|
45
|
de Vincenzo R, Scambia G, Benedetti Panici
P, Bonanno G, Ercoli A, Fattorossi A, Pernisco S, Isola G and
Mancuso S: Chemosensitizing effect of tamoxifen and ICI 182,780 on
parental and adriamycin-resistant MCF-7 human breast cancer cells.
Ann NY Acad Sci. 784:517–520. 1996.
|
